Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
COVID Symptoms |
Sees patients age 18 and up
Sees patients age 18 and up
Recognized by America's Top Doctors for 2017
Recognized by Best Doctors in America 2016
Recognized in Philadelphia magazine's annual Top Docs issues 2018 - 2021
Clinical expertise includes: Multiple Myeloma.
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Cancer immunotherapyVaccinesCellular therapyPhase I trialsCAR T cells
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AK, Parker TL, Menter A, Yang X, Parsons BM, Kumar P, Kapoor P, Rosenberg AS, Zonder JA, Faber EA, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial Lancet Oncology 21 (10): 1317-1330,2020.
Richardson PG, Lee HC, Abdalla A-O, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S: Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study Blood Cancer Journal 10 (10): 106,2020.
Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M.: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma Journal for Immunotherapy of Cancer 8 (2): e000734,2020.
AD Cohen, N Raje, J Fowler, K Mezzi, EC Sctoo, MV Dhodapkar: How to train your T cells: overcoming immune dysfunction in multiple myeloma Clinical Cancer Research 26 (7): 1541-1554,2020.
Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren E, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie BG, Orlowski RZ: Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma Clin Cancer Res
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah A-O, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facun T, Hulin C, Kortum M, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Pointek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD: Belantamab mafotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm randomised, open label, phase 2 study. Lancet Oncology 21 (2): 207-221,2020.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker K, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH: CRISPR-engineered T cells in patients with refractory cancer Science 367 (6481): eaba7365,2020.
Cohen AD: Myeloma: next-generation immunotherapy Hematology. American Society of Hematology Education Program. 2019 (1): 266-272,2019.
Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.: Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res
7 (10): 1633-1646,2019.
Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM: Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies Blood Advances 3 (16): 2487-2490,2019.
Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melenhorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma Blood Adv
3 (19): 2812-2815,2019.
Fajgenbaum DC, Langan R-A, Japp AS, Shilling D, Partridge HL, Pierson SK, Singh A, Ruth JR, Nabel CS, Stone K, Chaturvedi V, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Cohen AD, Krymskaya V, Rubenstein A, Betts M, Kambayashi T, Jordan MB, van Rhee F, Uldrick TS.: Identifying and Targeting Pathogenic PI3K/AKT/mTOR Signaling in IL-6-blockade-refractory Idiopathic Multicentric Castleman Disease J Clin Invest
130 (10): 4451-63,2019.
Cornell RF, Ky B, Weiss BM, Dahm C, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O’Quinn R, Savona MR, Slosky D, Smith AM, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Events during Proteastome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol 37 (22): 1946-1955,2019.
Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.: Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma Cancer Immunol Res
7 (4): 658-669,2019.
Trudel, S, Lendvai, N, Popat, R, Voorhees, P M., Reeves, B, Libby, E N., Richardson, P G., Hoos, A, Gupta, I, Bragulat, V, He, Z, Opalinska, J B., Cohen, A D.: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer 9 (4): 37,2019.
Susanibar Adaniya SP, Cohen AD*, Garfall AL*: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications American Journal of Hematology 94 (S1): S28-S33,2019.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma The Journal of Clinical Investigation 129 (6): 2210-2221,2019.
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson Jr. LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD: Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Lancet Oncology 19 (12): 1641-1653,2018.
Cohen AD: CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. American Society of Clinical Oncology Educational book 38 : e6-e15,2018.
Perelman Center for Advanced Medicine12th Floor, South PavilionOffice #12-1753400 Civic Center Blvd
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.